Fairfield, Bush & Co. Cyto Dyn Inc. Transaction History

Fairfield, Bush & Co.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 08, 2021	SELL	$1.27 - $2.46 $196,988 - $381,568	-155,109 Closed	0 $0
Q2 2021 Aug 02, 2021	BUY	$1.67 - $3.98 $48,764 - $116,216	29,200 Added 23.19%	155,109 $264,000
Q1 2021 May 14, 2021	BUY	$2.12 - $7.15 $155,078 - $523,022	73,150 Added 138.65%	125,909 $339,000
Q4 2020 Feb 12, 2021	BUY	$2.02 - $6.0 $16,564 - $49,200	8,200 Added 18.4%	52,759 $284,000
Q3 2020 Nov 18, 2020	BUY	$2.92 - $6.48 $28,496 - $63,238	9,759 Added 28.04%	44,559 $130,000
Q2 2020 Aug 13, 2020	BUY	$2.25 - $8.77 $78,300 - $305,196	34,800 New	34,800 $198,000

263K

Ticker CYDY
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 813,040,000
Market Cap $163M
Description
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as c...

Get notified when there are updates to the investment portfolio of Fairfield, Bush & Co., based on Form 13F filings with the SEC.

Stay updated on Fairfield, Bush & Co. with notifications on news.